Koji Kasanuki1, Keith A Josephs1, Tanis J Ferman1, Melissa E Murray1, Shunsuke Koga1, Takuya Konno1, Nobutaka Sakae1, Adam Parks1, Ryan J Uitti1, Jay A Van Gerpen1, Neill R Graff-Radford1, Zbigniew K Wszolek1, Dennis W Dickson2. 1. From the Departments of Neuroscience (K.K., M.E.M., S.K., N.S., J.A.V.G., D.W.D.), Psychiatry and Psychology (T.J.F., A.P.), and Neurology (T.K., R.J.U., N.R.G.-R., Z.K.W.), Mayo Clinic, Jacksonville, FL; and Behavioral Neurology (K.A.J.), Department of Neurology, Mayo Clinic, Rochester, MN. 2. From the Departments of Neuroscience (K.K., M.E.M., S.K., N.S., J.A.V.G., D.W.D.), Psychiatry and Psychology (T.J.F., A.P.), and Neurology (T.K., R.J.U., N.R.G.-R., Z.K.W.), Mayo Clinic, Jacksonville, FL; and Behavioral Neurology (K.A.J.), Department of Neurology, Mayo Clinic, Rochester, MN. dickson.dennis@mayo.edu.
Abstract
OBJECTIVE: To describe clinical and pathologic characteristics of diffuse Lewy body disease (DLBD) manifesting as corticobasal syndrome (CBS). METHODS: In 523 autopsy-confirmed cases of DLBD, we identified 11 patients diagnosed with CBS. For comparison, we studied 22 DLBD brains with antemortem presentation of dementia with Lewy bodies (DLB). Given previous studies suggesting the importance of pathology in peri-Rolandic cortices in CBS, we used digital pathology to count Lewy bodies and to quantify intracytoplasmic and neuritic α-synuclein and phospho-tau burden in the motor cortex. RESULTS: DLBD patients with antemortem features of CBS were significantly younger at disease onset and less likely to have REM sleep behavior disorder than DLBD cases who met clinical criteria for DLB during life. Patients with DLBD manifesting as CBS had more Lewy bodies in the motor cortex than DLBD manifesting as clinically probable DLB. Three cases had concomitant progressive supranuclear palsy and 4 cases had concomitant Alzheimer disease as probable correlates of CBS. CONCLUSION: The neuropathology underlying CBS is heterogeneous, including corticobasal degeneration, Alzheimer disease, and progressive supranuclear palsy. This study suggests that atypical variants of Lewy body disease with severe peri-Rolandic Lewy-related pathology can present clinically as CBS. Patients with DLBD who present as CBS tend to have an earlier age at onset and are less likely to have clinical features of DLB, such as dream enactment behavior during sleep, visual hallucinations, and levodopa-responsive parkinsonism. Future studies with biofluid or molecular imaging biomarkers for α-synuclein will permit better recognition of this uncommon pathologic substrate of CBS.
OBJECTIVE: To describe clinical and pathologic characteristics of diffuse Lewy body disease (DLBD) manifesting as corticobasal syndrome (CBS). METHODS: In 523 autopsy-confirmed cases of DLBD, we identified 11 patients diagnosed with CBS. For comparison, we studied 22 DLBD brains with antemortem presentation of dementia with Lewy bodies (DLB). Given previous studies suggesting the importance of pathology in peri-Rolandic cortices in CBS, we used digital pathology to count Lewy bodies and to quantify intracytoplasmic and neuritic α-synuclein and phospho-tau burden in the motor cortex. RESULTS: DLBD patients with antemortem features of CBS were significantly younger at disease onset and less likely to have REM sleep behavior disorder than DLBD cases who met clinical criteria for DLB during life. Patients with DLBD manifesting as CBS had more Lewy bodies in the motor cortex than DLBD manifesting as clinically probable DLB. Three cases had concomitant progressive supranuclear palsy and 4 cases had concomitant Alzheimer disease as probable correlates of CBS. CONCLUSION: The neuropathology underlying CBS is heterogeneous, including corticobasal degeneration, Alzheimer disease, and progressive supranuclear palsy. This study suggests that atypical variants of Lewy body disease with severe peri-Rolandic Lewy-related pathology can present clinically as CBS. Patients with DLBD who present as CBS tend to have an earlier age at onset and are less likely to have clinical features of DLB, such as dream enactment behavior during sleep, visual hallucinations, and levodopa-responsive parkinsonism. Future studies with biofluid or molecular imaging biomarkers for α-synuclein will permit better recognition of this uncommon pathologic substrate of CBS.
Authors: Naomi Kouri; Melissa E Murray; Anhar Hassan; Rosa Rademakers; Ryan J Uitti; Bradley F Boeve; Neill R Graff-Radford; Zbigniew K Wszolek; Irene Litvan; Keith A Josephs; Dennis W Dickson Journal: Brain Date: 2011-09-20 Impact factor: 13.501
Authors: S N Gomperts; D M Rentz; E Moran; J A Becker; J J Locascio; W E Klunk; C A Mathis; D R Elmaleh; T Shoup; A J Fischman; B T Hyman; J H Growdon; K A Johnson Journal: Neurology Date: 2008-09-16 Impact factor: 9.910
Authors: Hiroshige Fujishiro; Tanis J Ferman; Bradley F Boeve; Glenn E Smith; Neill R Graff-Radford; Ryan J Uitti; Zbigniew K Wszolek; David S Knopman; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson Journal: J Neuropathol Exp Neurol Date: 2008-07 Impact factor: 3.685
Authors: Ian G McKeith; Bradley F Boeve; Dennis W Dickson; Glenda Halliday; John-Paul Taylor; Daniel Weintraub; Dag Aarsland; James Galvin; Johannes Attems; Clive G Ballard; Ashley Bayston; Thomas G Beach; Frédéric Blanc; Nicolaas Bohnen; Laura Bonanni; Jose Bras; Patrik Brundin; David Burn; Alice Chen-Plotkin; John E Duda; Omar El-Agnaf; Howard Feldman; Tanis J Ferman; Dominic Ffytche; Hiroshige Fujishiro; Douglas Galasko; Jennifer G Goldman; Stephen N Gomperts; Neill R Graff-Radford; Lawrence S Honig; Alex Iranzo; Kejal Kantarci; Daniel Kaufer; Walter Kukull; Virginia M Y Lee; James B Leverenz; Simon Lewis; Carol Lippa; Angela Lunde; Mario Masellis; Eliezer Masliah; Pamela McLean; Brit Mollenhauer; Thomas J Montine; Emilio Moreno; Etsuro Mori; Melissa Murray; John T O'Brien; Sotoshi Orimo; Ronald B Postuma; Shankar Ramaswamy; Owen A Ross; David P Salmon; Andrew Singleton; Angela Taylor; Alan Thomas; Pietro Tiraboschi; Jon B Toledo; John Q Trojanowski; Debby Tsuang; Zuzana Walker; Masahito Yamada; Kenji Kosaka Journal: Neurology Date: 2017-06-07 Impact factor: 9.910
Authors: Ruben Smith; Michael Schöll; Håkan Widner; Danielle van Westen; Per Svenningsson; Douglas Hägerström; Tomas Ohlsson; Jonas Jögi; Christer Nilsson; Oskar Hansson Journal: Neurology Date: 2017-07-28 Impact factor: 9.910
Authors: Marina Buciuc; Jennifer L Whitwell; Koji Kasanuki; Jonathan Graff-Radford; Mary M Machulda; Joseph R Duffy; Edythe A Strand; Val J Lowe; Neill R Graff-Radford; Beth K Rush; Malgorzata B Franczak; Margaret E Flanagan; Matthew C Baker; Rosa Rademakers; Owen A Ross; Bernardino F Ghetti; Joseph E Parisi; Aditya Raghunathan; R Ross Reichard; Eileen H Bigio; Dennis W Dickson; Keith A Josephs Journal: Ann Neurol Date: 2020-12-17 Impact factor: 10.422
Authors: George Naasan; Tal Shany-Ur; Manu Sidhu; Cynthia Barton; Robin Ketelle; Suzanne M Shdo; Joel H Kramer; Bruce L Miller; William W Seeley Journal: Neurocase Date: 2019-04-22 Impact factor: 0.881
Authors: Nobutaka Sakae; Keith A Josephs; Irene Litvan; Melissa E Murray; Ranjan Duara; Ryan J Uitti; Zbigniew K Wszolek; Jay van Gerpen; Neil R Graff-Radford; Dennis W Dickson Journal: Alzheimers Dement Date: 2019-08-06 Impact factor: 16.655
Authors: Chiara Maria Giulia De Luca; Antonio Emanuele Elia; Sara Maria Portaleone; Federico Angelo Cazzaniga; Martina Rossi; Edoardo Bistaffa; Elena De Cecco; Joanna Narkiewicz; Giulia Salzano; Olga Carletta; Luigi Romito; Grazia Devigili; Paola Soliveri; Pietro Tiraboschi; Giuseppe Legname; Fabrizio Tagliavini; Roberto Eleopra; Giorgio Giaccone; Fabio Moda Journal: Transl Neurodegener Date: 2019-08-08 Impact factor: 8.014
Authors: Kunal C Potnis; Lauren B Flueckinger; Stephanie M DeArmey; Roy N Alcalay; Jeffrey W Cooney; Priya S Kishnani Journal: Mol Genet Metab Rep Date: 2018-10-18
Authors: Zerui Wang; Katelyn Becker; Vincenzo Donadio; Sandra Siedlak; Jue Yuan; Masih Rezaee; Alex Incensi; Anastasia Kuzkina; Christina D Orrú; Curtis Tatsuoka; Rocco Liguori; Steven A Gunzler; Byron Caughey; Maria E Jimenez-Capdeville; Xiongwei Zhu; Kathrin Doppler; Li Cui; Shu G Chen; Jiyan Ma; Wen-Quan Zou Journal: JAMA Neurol Date: 2020-09-28 Impact factor: 18.302